Among the different CCR7-expressing hematological tumors, we decided to study the benefits of an anti-CCR7 mAb on MCL due to the limited therapeutic options and an unmet need of alternative treatments for this hematologic disorder[21-23]. The gene discussed is CCR7; the disease is hematopoietic and lymphoid cell neoplasm.